Pd52-04 the Impact of Neoadjuvant Chemotherapy for Squamous Histology in Patients With Muscle Invasive Bladder Cancer
Year: 2019
Type: article
Abstract: elevated creatinine, hyponatremia;1-each: dehydration, emesis, neutropenic fever, infection).Gr 3/4 cytopenias occurred in 57% of pts.Of 36 pts who had RC the median time to surgery was 5.3 wks from last dose.Baseline stage was cT2 51%, cT3 44%, cT4a 5%.The PaIR was 61%.Sixteen pts were downstaged to pT0 (44.4%), 3 to pTis (8.3%), and 3 to pT1 (8.3%).PaIR did not correlate with baseline PD-L1 score.At 17.4 (1.6-33.3)months median follow up, the relapse free-, overall-, and disease specific-survival, was 70%, 81%, and 90%, respectively.CONCLUSIONS: Neoadjuvant chemo-immunotherapy with pembro in locally advanced UC has manageable toxicity, a comparable time to surgery as NAC, and has improved pathologic outcomes compared to historic controls.Furthermore, the long-term effects of immunotherapy with a sustained high disease specific survival may provide control rates that warrant further study.Clinical trial identification Clinicaltrials.
Source: The Journal of Urology
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2940599765